{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-098539","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.765673+00:00","generated_at":"2026-06-17T03:07:07.475078+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aeglea cuts 83% of workforce, explores strategic alternatives after mixed trial data","bullets":["Workforce reduced by 50 (~83% of headcount) to ~10 employees; $6.2M restructuring charges expected in Q2 2023.","CBO Michael Hanley and CMO Linda Neuman depart effective April 14, 2023.","Interim Phase 1/2 pegtarviliase trial: dose-dependent homocysteine reduction in cohorts 1–2 but not consistent in cohort 3; ADAs observed.","Company engages Wedbush Securities to explore strategic alternatives including sale or merger; no timetable set.","Pegzilarginase MAA under EMA review with potential EU decision in late 2023; partnered with Immedica."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-098539","json":"https://secwatch.observer/filing/0001193125-23-098539.json","markdown":"https://secwatch.observer/filing/0001193125-23-098539.md","text":"https://secwatch.observer/filing/0001193125-23-098539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/0001193125-23-098539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/d485603d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:07:07.475078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44c6db7b05","claim":"Linda Neuman departed as Chief Medical Officer at Spyre Therapeutics, Inc..","evidence_excerpt":"Michael Hanley, the Company’s Chief Business Officer, and Linda Neuman, the Company’s Chief Medical Officer, will be departing from the Company, effective April 14, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/0001193125-23-098539-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"departing"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"7d6e2a0321","claim":"Michael Hanley departed as Chief Business Officer at Spyre Therapeutics, Inc..","evidence_excerpt":"Michael Hanley, the Company’s Chief Business Officer, and Linda Neuman, the Company’s Chief Medical Officer, will be departing from the Company, effective April 14, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/0001193125-23-098539-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"departing"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"39b0faede771b1c0136df6d8ce4cbb9747d7bd9c","claim":"Spyre Therapeutics, Inc. announced a restructuring with charges of approximately $6.2 million (50 people, or approximately 83% of the Company’s existing headcount).","evidence_excerpt":"headcount, retaining approximately 10 employees. The restructuring was communicated to employees on April 11, 2023. The Company estimates that it will incur approximately $6.2 million in employee-related restructuring charges in connection with the restructuring, consisting of (i) approximately $5.6 million in cash-based expenses related to employee severance","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/0001193125-23-098539-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $6.2 million"},{"label":"Headcount","value":"50 people, or approximately 83% of the Company’s existing headcount"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}